Financials
- Market Capitalization 1.81 B
- Employee 110
- Founded 2024
- CEO N/A
- Website www.inhibrx.com
- Headquarter Delaware, United States
- FIGI BBG01MS5Q9G3
- Industry 生物工学
総売上高
当期純利益
1株当たり基本利益(基本EPS)
有利子負債合計
フリーキャッシュフロー
現金および現金同等物
株価収益率
-10.67
売上高対価格比率
—
Related tickers
| # | 名前 | 価格 | 24時間% | 7日% | 1か月% | 1年% | 時価総額 | 過去7日 | |
|---|---|---|---|---|---|---|---|---|---|
| 2052 | TSHA Taysha Gene Therapies, Inc. - Common Stock | 5.69 USD | -1.39% | -5.95% | -3.40% | +96.21% | 1.85 B USD | ||
| 2068 | RXRX Recursion Pharmaceuticals, Inc. - Class A Common Stock | 3.40 USD | +1.80% | +3.98% | +12.21% | -25.93% | 1.82 B USD | ||
| 2084 | NTLA Intellia Therapeutics, Inc. - Common Stock | 12.73 USD | -1.09% | -0.55% | +20.21% | -7.22% | 1.78 B USD | ||
| 2086 | SEPN Septerna, Inc. - Common Stock | 38.15 USD | -1.95% | -8.23% | +10.74% | +73.33% | 1.78 B USD |